Organic Chemistry, Invited / Award Lecture
OC-021
The Chemical Development of Adafosbuvir, a Nucleoside Phosphoramidate Prodrug for the Treatment of Hepatitis C Infection
1Chemical Process Research and Development, Janssen Pharmaceutica, Schaffhausen 8200, Switzerland, 2Chemical Process Research and Development, Janssen Pharmaceutica, Beerse 2340, Belgium
Over the last decades, nucleoside analogues have played significant roles in antiviral therapies and emerged as a well-established platform to treat cancer and viral infections. 4’-fluoro-2’-C-methyluridine was discovered as a potent inhibitor of hepatitis C virus RNA-polymerase. Phosphoramidate prodrug strategy was applied, leading to identify a clinical candidate Adafosbuvir (Alios 335). The route definition, the initial scale-up route, and the optimization towards large-scale production of Adafosbuvir will be discussed in this presentation.
